Dextromethorphan
- Generic Name
- Dextromethorphan
- Brand Names
- Auvelity, Benylin DM, Bromfed DM, Broncotron, Cepacol Sore Throat Plus Cough, Cheracol D, Children's Nyquil Cold and Cough, Chloraseptic Sore Throat + Cough, Coricidin Hbp Chest Congestion, Coricidin Hbp Cough and Cold, Creomulsion, DM, Dayquil Cough, Delsym, Delsym Cough Plus Chest Congestion DM, Delsym Cough Plus Soothing Action, Delsym Cough Relief Plus Soothing Action, Despec Reformulated Jun 2008, Diabetic Tussin DM, Dimetapp Long Acting Cough Plus Cold, Diphen, G-zyncof, Mucinex Children's Cough, Mucinex Cough, Mucinex DM, Nuedexta, Nyquil Cough, Pediacare Children's Cough and Congestion, Promethazine DM, Robafen Cough, Robafen DM, Robitussin 12 Hour Cough Relief, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Robitussin Nighttime Cough DM, Robitussin Pediatric Cough & Cold LA, Robitussin Pediatric Cough Suppressant, Safetussin DM, Safetussin PM, Scot-tussin DM, Scot-tussin Diabetic CF, Scot-tussin Sugar Free DM, Sudafed PE Children's Cold & Cough, Triaminic Day Time Cold & Cough, Tusnel Diabetic
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25NO
- CAS Number
- 125-71-3
- Unique Ingredient Identifier
- 7355X3ROTS
- Background
Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
- Indication
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicat...
- Associated Conditions
- Allergic cough, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Bronchitis, Coughing caused by Flu caused by Influenza, Fever, Flu caused by Influenza, Headache, Irritative cough, Itching of the nose, Itching of the throat, Major Depressive Disorder (MDD), Nasal Congestion, Pseudobulbar Affect (PBA), Rhinorrhoea, Sneezing, Cold or flu syndrome, Upper respiratory symptoms, Watery itchy eyes
- Associated Therapies
- Airway secretion clearance therapy, Bronchodilation, Oropharyngeal antisepsis
Add-On Therapy to Risperidonein Schizophrenia
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 161
- Registration Number
- NCT01189006
- Locations
- 🇨🇳
Ru-Band Lu, Tainan, Taiwan
Dextromethorphan and Silymarin in Chronic Kidney Disease (CKD) Patients
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT01091324
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Taian, Taiwan
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01017939
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 87
- Registration Number
- NCT00964106
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702
- Conditions
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00950586
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00920088
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
- Conditions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 92
- Registration Number
- NCT00873366
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
- Conditions
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00788047
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Vascular Endothelial Protection Effects of Dextromethorphan
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2008-01-31
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00605605
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Trial of Dextromethorphan in Rett Syndrome
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2014-04-23
- Target Recruit Count
- 38
- Registration Number
- NCT00593957
- Locations
- 🇺🇸
Kennedy Krieger Institute/Johns Hopkins Medical Institutions, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.